Compare Novartis AG (NVS) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Charles Schwab Corporation Common Stock — how do they compare? Novartis AG trades at $137.69 (market cap $262.64B), while Charles Schwab Corporation Common Stock trades at $106.54 (market cap $184.81B). The key difference: Novartis AG is the larger of the two by market cap, and Novartis AG pays the higher dividend (3.44%). Which is the better fit depends on your goals.
| NVS | SCHW | |
|---|---|---|
Market Cap | $262.64B | $184.81B |
Sector | Health | Financials |
52-Week High | $168.62 | $113.65 |
52-Week Low | $121.80 | $85.35 |
Enterprise Value | $303.97B | — |
Dividend Yield | 3.44% | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.
While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.
Charles Schwab (SCHW) trades at $106.87, down 2.21% today, as technical indicators signal bearish momentum with price near key support at $106. Fundamentally, the company shows strength with Q2 2026 EPS beating estimates at $1.62 versus $1.56 expected, and revenue growth accelerating to $23.92B in 2025. Analyst sentiment remains positive with 57% buy ratings and a $122.14 consensus target, representing 14% upside potential from current levels.
The outlook remains favorable given strong earnings momentum and expanding digital asset offerings, though near-term technical weakness and competitive pressures from Vanguard's Altruist acquisition present risks. With robust cash flow generation and improving debt metrics, SCHW offers value for long-term investors despite current bearish technical signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
